Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis
Fig 4
High titer of IF-ANA after IFX but not ADA therapy was related with ADrA appearance.
(a) The rate of HACA positive between 0–156 weeks was compared between IF-ANA titer after IFX of <320 and ≥320/ <640 and ≥640. (b) The rate of AAA positive between 0–52 weeks was compared between IF-ANA titer after ADA of <320 and ≥320/ <640 and ≥640. The percentages and absolute numbers of each group of patients are indicated just above the bar graphs. Fisher’s exact tests were used for comparison. IFX, infliximab; ADA, adalimumab; ADrA, anti-drug antibodies; HACA, anti-IFX antibodies; AAA, anti-ADA antibodies.